Compare Abbott Laboratories (ABT) vs Microsoft (MSFT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Microsoft — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Microsoft trades at $382.41 (market cap $2.89T). The key difference: Microsoft is far larger — about 17.3× Abbott Laboratories's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | MSFT | |
|---|---|---|
Market Cap | $166.94B | $2.89T |
Sector | Health | Technology |
52-Week High | $136.62 | $542.07 |
52-Week Low | $82.57 | $352.83 |
Enterprise Value | $193.69B | $2.87T |
Dividend Yield | 2.63% | 0.94% |
Volume | — | 36,654,621 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Microsoft trades at $382.74, down 1.03% today, with strong fundamentals including 36.14% net margin and consistent earnings beats. The stock shows bullish technical signals despite mixed indicators, with support at $379. Analyst consensus remains overwhelmingly positive with 80% buy ratings and a $550.43 price target. Recent news highlights Microsoft's AI leadership and cloud growth potential.
Outlook remains positive given Microsoft's dominant market position, AI integration across products, and robust financials. Risks include increased capital expenditure concerns and competitive pressures. The stock offers growth potential through Azure expansion and Copilot adoption, though investors should monitor execution on AI investments and macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
